Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) posted FCF Margin of 880.53% for Q3 2021, up 106.86% on a QoQ basis from 12835.99% in Q2 2021, and up 309972.0% year-over-year from N/an in Q3 2020.
Powered by 
Analysis
Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings has reported FCF Margin for 7 years, with the latest figure at 880.53% in Q3 2021.
- On a quarterly basis, FCF Margin rose 309972.0% year-over-year to 880.53% in Q3 2021; TTM through Jun 2022 was 32631.18%, a 2945821.0% decrease from a year earlier, with the FY2021 full-year figure at 5470.98%, down 292680.0% from the prior year.
- FCF Margin was 880.53% for Q3 2021 at Corbus Pharmaceuticals Holdings, up from 12835.99% in the prior quarter.
- The five-year high for FCF Margin was 880.53% in Q3 2021, with the low at 12835.99% in Q2 2021.
- Average FCF Margin over 5 years is 2105.27%, with a median of 810.77% recorded in 2017.
- The sharpest annual moves came in 2020 and 2021: FCF Margin sank 924062 bps in 2020, then soared 309972 bps in 2021.
- Over 5 years, FCF Margin stood at 800.85% in 2017, then climbed by 7 bps to 742.7% in 2018, then retreated by 25 bps to 926.88% in 2019, then sank by 198 bps to 2760.88% in 2020, then surged by 132 bps to 880.53% in 2021.
- The last three FCF Margin figures came in at 880.53% (Q3 2021), 12835.99% (Q2 2021), and 3366.58% (Q1 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Corbus Pharmaceuticals Holdings | 101.29 Mn | -61.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 880.53% |
| Jun 30, 2021 | -12,835.99% |
| Mar 31, 2021 | -3,366.58% |
| Dec 31, 2020 | -2,760.88% |
| Sep 30, 2020 | -2,219.20% |
| Jun 30, 2020 | -9,297.60% |
| Mar 31, 2020 | -1,592.73% |
| Dec 31, 2019 | -926.88% |
| Sep 30, 2019 | -705.78% |
| Jun 30, 2019 | -56.97% |
| Mar 31, 2019 | 543.29% |
| Dec 31, 2018 | -742.70% |
| Sep 30, 2018 | -820.69% |
| Jun 30, 2018 | -730.02% |
| Mar 31, 2018 | -301.86% |
| Sep 30, 2017 | -800.85% |
| Jun 30, 2017 | -1,643.80% |
| Mar 31, 2017 | -516.06% |
| Sep 30, 2016 | -420.29% |
| Jun 30, 2016 | -655.84% |